LO
Lotus Eye Hospital & Institute Ltd (LOTUSEYE)
₹101.12
Mkt cap
₹211 Cr
P/E ratio
479.00
P/B
3.44
Div yield
0.00%
ROE
0.13%
ROCE
1.41%
EPS (TTM)
₹0.21
Book value
₹29
52W range
98–147
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services. [1]
NSE LOTUSEYEBSE 532998
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−31.21% from high₹101
₹98+3.62% from low₹147
Current
₹101.12
Prev close
₹102.25
Day
−1.11%
Price performance
1D
−0.24%
1W
−1.00%
1M
−7.92%
3M
−12.90%
6M
−5.41%
1Y
−7.88%
YTD
−16.91%
Financials
Revenue, profit & margin
P/E ratio
479.0×
LOTUSEYE is 838% above the sector median of 51.1×
LOTUSEYE479.0×
Sector median51.1×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.73 | 12.03 | 10.88 | 12.89 | 12.91 | 12.25 | 11.51 | 13.52 | 13.04 | 13.55 | 13.61 | 17.06 | 17.72 | |
| YoY Sales growth | +7.34% | -0.91% | -2.60% | +2.55% | +1.41% | +1.83% | +5.79% | +4.89% | +1.01% | +10.61% | +18.25% | +26.18% | +35.89% | |
| Expenses | 10.92 | 10.45 | 10.12 | 11.23 | 11.76 | 11.46 | 11.68 | 12.04 | 12.27 | 12.89 | 13.13 | 14.11 | 15.17 | |
| Operating Profit | 1.81 | 1.58 | 0.76 | 1.66 | 1.15 | 0.79 | -0.17 | 1.48 | 0.77 | 0.66 | 0.48 | 2.95 | 2.55 | |
| OPM % | 14.22% | 13.13% | 6.99% | 12.88% | 8.91% | 6.45% | -1.48% | 10.95% | 5.90% | 4.87% | 3.53% | 17.29% | 14.39% | |
| Other Income | 0.28 | 0.34 | 0.40 | 0.31 | 0.27 | 0.22 | 0.52 | 0.19 | 0.27 | 0.24 | 0.47 | 0.21 | 0.30 | |
| Interest | 0.01 | 0.04 | 0.03 | 0.06 | 0.08 | 0.13 | 0.09 | 0.12 | 0.12 | 0.29 | 0.33 | 0.51 | 0.59 | |
| Depreciation | 0.89 | 0.98 | 1.12 | 1.06 | 1.23 | 1.31 | -0.58 | 0.82 | 0.85 | 0.98 | 1.10 | 1.64 | 1.70 | |
| Profit before tax | 1.19 | 0.90 | 0.01 | 0.85 | 0.11 | -0.43 | 0.84 | 0.73 | 0.07 | -0.37 | -0.48 | 1.01 | 0.56 | |
| Tax % | 28.57% | 26.67% | -200.00% | 28.24% | 9.09% | -44.19% | 70.24% | 24.66% | -71.43% | -29.73% | -33.33% | 39.60% | 21.43% | |
| Net Profit | 0.85 | 0.66 | 0.02 | 0.62 | 0.10 | -0.24 | 0.25 | 0.54 | 0.12 | -0.26 | -0.32 | 0.61 | 0.44 | |
| EPS in Rs | 0.41 | 0.32 | 0.01 | 0.30 | 0.05 | -0.12 | 0.12 | 0.26 | 0.06 | -0.13 | -0.15 | 0.29 | 0.21 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202640.14%Promoter
Promoters40.14%
FIIs0.00%
DIIs0.02%
Public59.85%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | ₹8,821.00 | 56.02 | 1,26,832 | 0.23% | 660 | +30.04% | 7,615 | +23.04% | 17.45% |
| Max Healthcare | ₹1,022.85 | 70.09 | 99,557 | 0.20% | 414 | −15.54% | 2,569 | +20.31% | 14.71% |
| Manipal Health | ₹688.85 | 96.62 | 90,610 | 0.00% | 285 | +10.29% | 3,399 | +37.32% | 12.10% |
| Aster DM Quality | ₹731.00 | 121.55 | 63,719 | 0.41% | 322 | +148.12% | 2,829 | +136.32% | 11.57% |
| Fortis Health. | ₹793.55 | 55.84 | 59,910 | 0.13% | 320 | +2.01% | 2,735 | +17.30% | 13.45% |
| Narayana Hrudaya | ₹1,891.30 | 42.72 | 38,651 | 0.24% | 301 | +16.61% | 2,844 | +73.01% | 15.50% |
| Global Health | ₹1,436.60 | 59.66 | 38,627 | 0.03% | 219 | +51.38% | 1,469 | +33.64% | 17.37% |
| Lotus Eye Hospit | ₹101.30 | 478.80 | 211 | 0.00% | 0 | +233.33% | 18 | +35.89% | 1.41% |
| Median: 31 Co. | ₹493.95 | 51.09 | 7,101 | 0.00% | 40 | +22.67% | 431 | +22.77% | 14.62% |
Filings
Annual reports15
Concall transcripts2
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Nov - Newspaper Advertisements published for Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Nov - Q2 FY27 revenue rose 36% to ₹17.72 crore; H1 revenue up 31% and net profit up 59%.Standalone Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026. 11 Nov - Q2/H1 FY27 unaudited results approved; net profit Rs105.32 lakh.Board Meeting Outcome for Standalone Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026. 11 Nov - Board approved Q2/H1 FY2026 unaudited results; net profit Rs105.32 lakh, revenue Rs3,523.93 lakh.Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 2 Nov - Board meeting on November 11, 2026 to approve Q2 and half-year standalone results; trading window to reopen after 48 hours.





